Dr. Trepanier earned his Ph.D. in clinical chemistry at the University of Windsor and completed his postdoctoral fellowship at the University of Alberta specializing in analytical chemistry. With over 25 years’ field experience in the pharmaceutical industry, he brings direct hands-on expertise in drug discovery; analytical and bioanalytical method development and analysis; preclinical pharmacokinetic, toxicological, and toxicokinetic studies; formulation development; drug manufacturing; and the preparation of preclinical regulatory submissions. He also has substantial experience working with contract research organizations and patent attorneys. 

Dr. Trepanier is the developer of Aurinia Pharmaceuticals LUPKYNIS® formulation which is used by thousands of lupis nephritis patients. Dr. Trepanier is the author or co-author of numerous scientific papers, abstracts and patents.